Evidence map›Paper›PMID 42403539›Full record

ReviewInternational journal of nanomedicine2026

Natural Product-Based Nanomicelles: Properties, Fabrication Strategies, and Therapeutic Applications in Diseases.

Jiaxin Yang, Zhiying Feng, Jingmin Fu, Jiawang Huang, Siyu Wang, Ling Li

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiaxin Yang *College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.ORCID 0009-0006-7772-5319
Zhiying Feng *College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.ORCID 0009-0000-9125-4687
Jingmin FuCollege of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.ORCID 0009-0003-8790-6349
Jiawang HuangCollege of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.ORCID 0000-0001-7787-9656
Siyu WangCollege of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.ORCID 0009-0003-2644-0936
Ling LiCollege of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.ORCID 0000-0002-9900-3695

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many bioactive natural products suffer from poor water solubility, rapid metabolism, and low bioavailability, which severely limit their clinical application. Natural product‑based nanomicelles (NSNs), which integrate the delivery functions of nanocarriers with the intrinsic therapeutic activities of the materials themselves, offer a promising solution to this dilemma. NSNs are self‑assembled nanoscale delivery systems constructed from natural small molecules, natural polymers, and their derivatives. This review provides a systematic overview of NSNs. We first summarize their main fabrication strategies, including nanoprecipitation, dialysis, thin‑film hydration, chemical conjugation, and electrostatic interaction, and compare the biological characteristics of NSNs with those of synthetic polymer micelles. The core advantages of NSNs include excellent biocompatibility, intrinsic lesion‑targeting capability, and drug‑excipient synergy. Subsequently, we detail the mechanisms and therapeutic applications of NSNs in six major disease areas: anti‑infection, oncology, inflammation and autoimmune diseases, metabolic diseases, fibrotic diseases, and nervous system disorders. A cross‑disease analysis reveals that modulation of oxidative stress is a common core mechanism underlying the therapeutic benefits of NSNs. Finally, we critically discuss the major barriers to clinical translation, such as batch‑to‑batch variability of natural materials and good manufacturing practice compliance, and propose future directions including mechanism‑driven rational design, theranostics, and manufacturing scalability.

Indexed as

Biological ProductsMicellesNanoparticle Drug Delivery SystemAnimalsHumansBiological ProductsMicellesNanoparticle Drug Delivery Systemclinical translationdisease treatmentdrug deliverynanomicellesnatural productsstimuli-responsive

Identifiers

PMID42403539
PMCPMC13332784

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.